RESUMO
Allopurinol is the most commonly used drug for the treatment of hyperuricemia in people, and in view of the risks of fatal hypersensitivity in patients with renal dysfunction, doses based on the glomerular filtration rate are proposed. In veterinary medicine, allopurinol is used in the treatment of canine leishmaniasis (CanL) caused by Leishmania infantum owing to the drug action of inhibiting the parasite's RNA synthesis. However, renal dysfunction frequently ensues from disease progression in dogs. The purpose of the present study was to standardize and validate a sensitive high-performance liquid chromatography-mass spectrometric (HPLC-MS/MS) method to determine the concentration of allopurinol and its active metabolite oxypurinol in canine urine for clinical pharmacokinetic investigation. Urine samples of eleven (11) dogs with naturally occurring CanL and in the maintenance phase of the treatment with alopurinol were used. For the chromatographic analysis of urine, the mobile phase consisted of a solution of 0.1 % formic acid (88 %) in 10â¯mM ammonium acetate. Separation of allopurinol and oxypurinol occurred in a flow of 0.8â¯mL/min on a C8 reverse phase column 5⯵m, and acyclovir was the internal standard. The HPLC-MS/MS method was validated by reaching the limits of detection and quantification, reproducibility and linearity. The lower limit of quantification achieved by the method was 10⯵g/mL for both allopurinol and oxypurinol. Calibration curves were prepared in blank urine added with allopurinol at concentrations of 10-1000⯵g/mL, and oxypurinol at 10-200⯵g/mL. Coefficients of variation of less than 15 % between intracurrent and intercurrent accuracy values were observed for both allopurinol and oxypurinol. Urine test samples remained stable after being subjected to freeze-thaw cycles and remaining at room temperature for 4â¯h. The method proved to be adequate to quantify allopurinol and oxypurinol in urine samples from dogs under treatment.
Assuntos
Alopurinol/urina , Cães/urina , Monitoramento de Medicamentos/veterinária , Leishmaniose/veterinária , Oxipurinol/urina , Administração Oral , Alopurinol/administração & dosagem , Alopurinol/farmacocinética , Animais , Cromatografia Líquida de Alta Pressão/métodos , Cães/parasitologia , Monitoramento de Medicamentos/métodos , Leishmania infantum/isolamento & purificação , Leishmaniose/tratamento farmacológico , Leishmaniose/parasitologia , Limite de Detecção , Masculino , Oxipurinol/farmacocinética , Reprodutibilidade dos Testes , Espectrometria de Massas em Tandem/métodosRESUMO
Fabrication of nitrogen-doped carbon dots (N-CDs) electrode for the screening of purine metabolic disorder was described in this paper. Peroxynitrite is a short-lived oxidant species that is a potent inducer of cell death. Uric acid (UA) can scavenge the peroxynitrite to avoid the formation of nitrotyrosine, which is formed from the reaction between peroxynitrite and tyrosine (Try). Scavenging the peroxynitrite avoids the inactivation of cellular enzymes and modification of the cytoskeleton. Reduced level of UA decreases the ability of the body from preventing the peroxynitrite toxicity. On the other hand, the abnormal level of UA leads to gout and hyperuricemia. Allopurinol (AP) is administered in UA lowering therapy. Thus, the simultaneous determination of UA, Try and AP using N-CDs modified glassy carbon (GC) electrode was demonstrated for the first time. Initially, N-CDs were prepared from L-asparagine by pyrolysis and characterized by different spectroscopic and microscopic techniques. The HR-TEM image shows that the average size of the prepared N-CDs was 1.8±0.03nm. Further, the N-CDs were directly attached on GC electrode by simple immersion, follows Micheal's nucleophilic addition. XPS of N-CDs shows a peak at 285.3eV corresponds to the formation of C-N bond. The GC/N-CDs electrode shows higher electrocatalytic activity towards UA, Tyr and AP by not only shifting their oxidation potentials toward less positive potential but also enhanced their oxidation currents in contrast to bare GC electrode. The GC/N-CDs electrode shows the limit of detection of 13×10-10M (S/N=3) and the sensitivity of 924µAmM-1cm-2 towards the determination of UA. Finally, the N-CDs modified electrode was utilized for the determination of UA, Tyr and AP in human blood serum and urine samples.
Assuntos
Técnicas Biossensoriais/métodos , Doenças Metabólicas/sangue , Doenças Metabólicas/urina , Ácido Úrico/sangue , Ácido Úrico/urina , Alopurinol/sangue , Alopurinol/urina , Asparagina/química , Carbono/química , Eletroquímica , Gota/diagnóstico , Gota/metabolismo , Humanos , Hiperuricemia/diagnóstico , Hiperuricemia/metabolismo , Nitrogênio/química , Oxirredução , Polímeros/química , Purinas/metabolismo , Tiadiazóis/química , Tirosina/sangue , Tirosina/urinaRESUMO
Allopurinol is used widely for the treatment of gout, but its pharmacokinetics is complex and some patients show hypersensitivity, necessitating careful monitoring and improved detection methods. In this study, a sensitive and reliable liquid chromatography-tandem mass spectrometry method was developed to determine the concentrations of allopurinol and its active metabolite oxypurinol in human plasma and urine using 2,6-dichloropurine as the internal standard (IS). Analytes and the IS were extracted from 0.5ml aliquots of plasma or urine using ethyl acetate and separated on an Agilent Eclipse Plus C18 column using methanol and ammonium formate-formic acid buffer containing 5mM ammonium formate and 0.1% formic acid (95:5, v/v) as the mobile phase (A) for allopurinol or methanol plus 5mM ammonium formate aqueous solution (95:5, v/v) as the mobile phase (B) for oxypurinol. Allopurinol was detected in positive ion mode and the analysis time was about 7min. The calibration curve was linear from 0.05 to 5µg/mL allopurinol in plasma and 0.5-30µg/mL in urine. The lower limit of quantification (LLOQ) was 0.05µg/mL in plasma and 0.5µg/mL in urine. The intra- and inter-day precision and relative errors of quality control (QC) samples were ≤11.1% for plasma and ≤ 8.7% for urine. Oxypurinol was detected in negative mode with an analysis time of about 4min. The calibration curve was linear from 0.05 to 5µg/mL in plasma (LLOQ, 0.05µg/mL) and from 1 to 50µg/mL in urine (LLOQ, 1µg/mL). The intra- and inter-day precision and relative errors were ≤7.0% for plasma and ≤9.6% for urine. This method was then successfully applied to investigate the pharmacokinetics of allopurinol and oxypurinol in humans.
Assuntos
Alopurinol/farmacocinética , Cromatografia Líquida/métodos , Supressores da Gota/farmacocinética , Oxipurinol/farmacocinética , Espectrometria de Massas em Tandem/métodos , Alopurinol/sangue , Alopurinol/urina , Calibragem , Supressores da Gota/sangue , Supressores da Gota/urina , Humanos , Limite de Detecção , Oxipurinol/sangue , Oxipurinol/urina , Padrões de Referência , Reprodutibilidade dos Testes , Espectrometria de Massas por Ionização por ElectrosprayRESUMO
Xanthinuria is a rare autosomal recessive disorder associated with a deficiency of xanthine oxidoreductase (XOR), which normally catalyzes the conversion of hypoxanthine to uric acid. The effects of this deficit are an elevated concentration of hypoxanthine and xanthine in the blood and urine, hypouricemia, and hypouricuria. The deficit in XOR can be isolated (type I xanthinuria) or associated with a deficit in aldehyde oxidase (type II xanthinuria) and sulfite oxidase (type III xanthinuria). While the first two variants have a benign course, are often asymptomatic (20%), and clinically indistinguishable, type III xanthinuria is a harmful form that leads to infant death due to neurological damage. The clinical symptoms (kidney stones, CKD, muscle and joint pain, peptic ulcer) are the result of the accumulation of xanthine, which is highly insoluble, in the body fluids. We describe a case of type I xanthinuria in a 52-year-old woman who presented with hypouricemia, hypouricuria and kidney stones. The diagnosis was based on purine catabolite levels in urine and serum measured by 3 nonroutine methods: high-pressure liquid chromatography, mass spectrometry, and magnetic resonance imaging. To identify the type of xanthinuria the allopurinol test was used. We believe that these tests will facilitate the diagnosis of xantinuria especially in asymptomatic patients without the need for a biopsy of the liver or intestines, which is useful only for scientific purposes.
Assuntos
Hipoxantinas , Erros Inatos do Metabolismo da Purina-Pirimidina/complicações , Erros Inatos do Metabolismo da Purina-Pirimidina/diagnóstico , Ácido Úrico , Xantina/urina , Alopurinol/urina , Biomarcadores/sangue , Biomarcadores/urina , Cromatografia Líquida de Alta Pressão , Feminino , Humanos , Hipertensão/etiologia , Hipoxantinas/sangue , Hipoxantinas/urina , Imageamento por Ressonância Magnética , Espectrometria de Massas , Pessoa de Meia-Idade , Nefrolitíase/etiologia , Valor Preditivo dos Testes , Erros Inatos do Metabolismo da Purina-Pirimidina/sangue , Erros Inatos do Metabolismo da Purina-Pirimidina/dietoterapia , Erros Inatos do Metabolismo da Purina-Pirimidina/urina , Sensibilidade e Especificidade , Resultado do Tratamento , Ácido Úrico/sangue , Ácido Úrico/urina , Xantina/sangueRESUMO
The allopurinol test aims to distinguish carriers and noncarriers for ornithine transcarbamylase (OTC) deficiency. We have evaluated the reliability of the test in at-risk females of known genotype. Results based on urine orotidine and/or orotic acid measurement were compared in terms of sensitivity and specificity. Retrospectively, we analysed the results of allopurinol tests in 42 women (22 confirmed heterozygotes and 20 noncarriers) from 23 pedigrees at risk of being carriers for OTC deficiency. Using a cut-off of 2 standard deviations above the mean of controls, the highest sensitivity (91%) was given by orotidine alone or in combination with orotic acid, but specificity was only 70% and 65%, respectively. We conclude that the value of the allopurinol test for detecting OTC carriers in at-risk females is limited. This needs to be recognized when counselling families. The test still has a role as a safe, quick, noninvasive screen of individuals at risk, but test results in possible carriers should be interpreted with caution. In the absence of other supportive evidence, confirmation by mutation analysis is required.
Assuntos
Alopurinol/urina , Triagem de Portadores Genéticos/métodos , Programas de Rastreamento/normas , Doença da Deficiência de Ornitina Carbomoiltransferase/diagnóstico , Ornitina Carbamoiltransferase/genética , Adulto , Feminino , Genótipo , Humanos , Recém-Nascido , Masculino , Programas de Rastreamento/métodos , Doença da Deficiência de Ornitina Carbomoiltransferase/epidemiologia , Doença da Deficiência de Ornitina Carbomoiltransferase/genética , Doença da Deficiência de Ornitina Carbomoiltransferase/urina , Linhagem , Reprodutibilidade dos Testes , Estudos Retrospectivos , Fatores de RiscoRESUMO
A very simple, rapid and highly sensitive method has been developed for the determination of allopurinol. The method is based on the room temperature phosphorescence of allopurinol in sodium dodecylsulphate (SDS) micelles, with thallium (I) providing the external heavy atom and sodium sulphite acting as the oxygen scavenger. Under the optimum experimental conditions, the range of application is 0.25-7.0 microg ml(-1) and the limit of detection is 0.014 microg ml(-1). The most relevant characteristic of this method is its great selectivity, e.g. allopurinol can be determined in the presence of its metabolite, oxypurinol. The results of the analysis of several pharmaceutical preparations were satisfactory. The clinical applicability of this procedure has been tested by analysing allopurinol in urine samples.
Assuntos
Alopurinol/análise , Medições Luminescentes , Micelas , Temperatura , Alopurinol/urina , HumanosRESUMO
A 60-year-old Japanese man was diagnosed as having hypouricemia at an annual health check-up. The routine laboratory data was not remarkable except that the patient's hypouricemia and plasma levels of xanthine and hypoxanthine were much higher than those of normal subjects. Furthermore, the patient's daily urinary excretion of xanthine and hypoxanthine was markedly increased compared with reference values. The xanthine dehyrogenase activity of the duodenal mucosa was below the limits of detection. Nevertheless, allopurinol was metabolized to oxypurinol in vivo. Based on these findings, a subtype of classical xanthinuria (type I) was diagnosed. The xanthine dehyrogenase protein was detected by Western blotting analysis. Sequencing of the cDNA of the xanthine dehyrogenase obtained from the duodenal mucosa revealed that a point mutation of C to T had occurred in nucleotide 445. This changed codon 149 from CGC (Arg) to TGC (Cys), a finding that has not been previously reported in patients with classical xanthinuria type I.
Assuntos
Hipoxantina/urina , Mutação Puntual , Erros Inatos do Metabolismo da Purina-Pirimidina/enzimologia , Xantina Desidrogenase/genética , Xantina/urina , Alopurinol/administração & dosagem , Alopurinol/urina , Humanos , Hipoxantina/sangue , Masculino , Pessoa de Meia-Idade , Oxipurinol/urina , Erros Inatos do Metabolismo da Purina-Pirimidina/genética , Erros Inatos do Metabolismo da Purina-Pirimidina/fisiopatologia , Erros Inatos do Metabolismo da Purina-Pirimidina/urina , Análise de Sequência de DNA , Xantina/sangue , Xantina Desidrogenase/metabolismoRESUMO
AIMS: The prevalence of hyperuricaemia and gout increases with age as does the incidence of adverse effects to allopurinol, the major uric acid lowering drug. The present study was performed to compare the disposition and effects of allopurinol and its active metabolite oxipurinol in elderly and young subjects without major health problems. METHODS: Ten elderly (age range 71-93 years) and nine young subjects (24-35 years) received an oral dose of 200 mg allopurinol in an open, single dose, cross sectional design. Four of these individuals were additionally dosed with 200 mg allopurinol intravenously. Plasma and urine concentrations of allopurinol, oxipurinol, hypoxanthine, xanthine, and uric acid were measured by h. p.l.c. RESULTS: Total clearance of allopurinol was not different in elderly (15.7+/-3.8 ml min-1 kg-1, mean+/-s.e. mean) and young subjects (15.7+/-2.1), whereas total clearance of oxipurinol was significantly reduced in the aged (0.24+/-0.03) compared with young controls (0.37+/-0.05) as was the distribution volume of oxipurinol (0.60+/-0.09 and 0.84+/-0.07 l kg-1, respectively). Oxipurinol was eliminated primarily by the kidneys, allopurinol by metabolism. Fractional peroral bioavailability of allopurinol was 0.81+/-0.16 (n=4, two elderly and two young subjects). Although maximal plasma concentrations of oxipurinol were significantly higher in elderly (5. 63+/-0.83 microgram ml-1 ) than in young persons (3.75+/-0.25) as was the area under the oxipurinol plasma concentration-time curve, AUC (260+/-46 and 166+/-23 microgram ml-1 h, respectively), the pharmacodynamic effect of oxipurinol was smaller in elderly than young subjects (time-dependent decrease of plasma uric acid 83+/-30 microgram ml-1 h in elderly compared with 176+/-21 in young controls). Oxipurinol increased the renal clearance of xanthine, suggesting inhibition of tubular xanthine reabsorption by oxipurinol. CONCLUSIONS: Although allopurinol elimination is not reduced in the aged, that of its active metabolite oxipurinol is because of an age-dependent decline in renal function. Xanthine oxidase inhibition by oxipurinol appears to be reduced in old age. In addition to its uricostatic action, oxipurinol has a xanthinuric effect which is also diminished in the elderly.
Assuntos
Alopurinol/farmacologia , Alopurinol/farmacocinética , Oxipurinol/farmacologia , Oxipurinol/farmacocinética , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Alopurinol/sangue , Alopurinol/urina , Área Sob a Curva , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão , Interações Medicamentosas , Feminino , Humanos , Hipoxantina/sangue , Hipoxantina/urina , Masculino , Oxipurinol/sangue , Oxipurinol/urina , Fatores de Tempo , Ácido Úrico/sangue , Ácido Úrico/urina , Xantina/sangue , Xantina/urinaRESUMO
A influencia do ion superoxido na evolution da nefropatia por adriamicina foi avaliada usando-se alopurinol para inibir sua sintese.Sessenta ratos Wistar machos foram divididos em 6 grupos.No primeiro dia do experimento 3 grupos receberam salina(GCS,GCSTA eGCSTC) e 3 receberam adriamicina(GNC,GNTA,GNTC)Dois grupos(GCSTA eGNTA)foram tratados com alopurinol 3 horas antes e 1 minuto depois da inoculacao com salina(GCTA) ou adriamicina(GNTA).em dois grupos adicionais o tratamento com alopurinol foi mantido ate o fim do experimento(4 semanas).Os grupos tratados com adriamicina apresentaram proteinuria macica da semana 2 ate a semana 4.Apenas na semana 2 observou-se diferenca estatistica entre a proteinuria dos tres grupos tratados com adriamicina.((GNC=129,2+ou -17,5mg/24h:GNTA=85,4+ ou -15,9mg/24h:GNTC=87,8+ ou -15,9mg/24h;p maior0,01)A microscopia optica os animais inoculados com adriamicina apresentaram somente lesoes tubulo-intersticiais tais como cilindros intratubulares,dilatacao e atrofia tubular e infiltrado inflamatorio intersticial.Nao houve diferenca significativa do indice de lesao tubulo-interstitical entre os tres grupos nefroticos(GNC=8;GNTA=6;GNTC=4;p menor0,05).Conclusao:Em ratos com nefropatia por adriamicina,o uso de alopurinol associou-se com diminuicao transitoria da proteinuria,mas nao alterou a lesao tubulo-intersticial
Assuntos
Animais , Ratos , Alopurinol/administração & dosagem , Alopurinol/efeitos adversos , Alopurinol/urina , Nefropatias/induzido quimicamente , Nefropatias/fisiopatologiaRESUMO
OBJECTIVES: To evaluate the in vivo effect of xanthine oxidase (XO) inhibition by allopurinol on the determination of polymorphic N-acetyltransferase 2 (NAT2) and cytochrome P450 1A2 (CYP1A2) with urinary caffeine metabolic ratios. METHODS: In an open, prospective study involving 21 healthy subjects (eight fast, 13 slow NAT2 acetylators) allopurinol (300 mg perday) was administered orally on trial days 1-8, followed by a wash-out period of 8 days. Urinary caffeine tests (200 mg caffeine p.o.) were performed repetitively. Urine was collected for 8 h and venous blood samples for the determination of allopurinol, oxypurinol and uric acid were drawn. The urinary caffeine metabolites 1-methyluric acid (1MU), 1-methylxanthine (1MX), 1,7-dimethyluric acid (17MU), 1,7-dimethylxanthine (17MX), 5-acetylamino-6-formylamino-3-methyluracil (AFMU), plasma allopurinol and oxypurinol were analysed using high-performance liquid chromatography (HPLC). RESULTS: During XO inhibition by allopurinol, the formation of 1MU from 1MX and therefore the XO ratio 1MU/1MX decreased to 15.9 (1.2)% [mean with (SEM)] of baseline values (P < 0.005). The NAT2 ratio AFMU/1MX decreased likewise to 56.7 (6.3)% (P < 0.005). AFMU/(AFMU + 1MX + 1MU), an alternative NAT2 ratio, remained constant, but the CYP1A2 ratio (AFMU + 1MX + 1MU)/17MU, used to express CYP1A2 activity, transiently increased to 167 (13)% (P < 0.005). The NAT2 phenotype did not influence CYP1A2 and XO ratios or plasma oxypurinol pharmacokinetics. CONCLUSIONS: Several caffeine metabolic ratios are commonly used to express the activities of NAT2, CYP1A2 and XO both in healthy volunteers and in polymedicated patients, although their reliability has not been evaluated thoroughly during concurrent drug administration. The findings of this study suggest that NAT2 phenotyping should be performed using the ratio AFMU/(AFMU + 1MX + 1MU) if an XO inhibitor may be present. It also shows that the determination of CYP1A2 activity with caffeine as a metabolic probe is considerably altered under these conditions. Thus, concomitant drug administration may impair the robustness of multiple pathways of the complex caffeine test. This points to the need for alternative probes, designed to assess only the activity of a single enzyme because, in contrast to healthy volunteers, in patients known or unknown drug interactions may often be present.
Assuntos
Alopurinol/farmacologia , Arilamina N-Acetiltransferase/metabolismo , Cafeína/urina , Citocromo P-450 CYP1A2/metabolismo , Xantina Oxidase/antagonistas & inibidores , Alopurinol/urina , Arilamina N-Acetiltransferase/efeitos dos fármacos , Biomarcadores , Cafeína/metabolismo , Cromatografia Líquida de Alta Pressão , Citocromo P-450 CYP1A2/efeitos dos fármacos , Relação Dose-Resposta a Droga , Feminino , Humanos , Masculino , Oxipurinol/sangue , Estudos Prospectivos , Ácido Úrico/sangueRESUMO
1. Eight healthy subjects received 50, 100, 300, 600 and 900 mg allopurinol daily for 1 week each, in random order with 1 week separating each treatment period. The pre-dose plasma concentration of oxypurinol, the extent of inhibition of xanthine oxidase, plasma urate concentration and urine urate excretion rate were assessed on the last 2 days of each treatment week. 2. The ratio of 1-methyluric acid (1MU) over 1-methylxanthine (1MX) in the urine, following a dose of 50 mg 1MX infused intravenously over 20 min, was used to measure the inhibition of xanthine oxidase. 3. The steady-state plasma concentration of oxypurinol increased linearly with increasing dose of allopurinol between 50 mg to 600 mg day-1, with a weak indication of saturation at the higher 900 mg day-1 dose rate. 4. The relationships between plasma oxypurinol concentration and xanthine oxidase inhibition (1MU/1MX ratio), plasma urate concentration and urine urate excretion rate were fitted to an inhibition sigmoid Emax model and the C50 values for oxypurinol were 26.38 +/- 4.87, (mean +/- s.d.) 36.58 +/- 8.36 and 24.61 +/- 9.08 microM, respectively. 5. 1MU/1MX ratio appeared to be a reliable index of xanthine oxidase activity in vivo as the C50 for oxypurinol observed for 1MU/1MX ratio, plasma urate concentration and urine urate excretion rate were similar. 6. The concentration of oxypurinol required for inhibition of xanthine oxidase, as indicated by C50, was lower than those often observed in clinical practice.
Assuntos
Alopurinol/administração & dosagem , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/farmacocinética , Oxipurinol/farmacocinética , Adulto , Alopurinol/sangue , Alopurinol/farmacocinética , Alopurinol/urina , Quimioterapia Combinada , Inibidores Enzimáticos/sangue , Inibidores Enzimáticos/urina , Feminino , Humanos , Masculino , Oxipurinol/sangue , Xantina Oxidase/sangue , Xantina Oxidase/urinaRESUMO
Allopurinol or pyrazinamide was administered to rats treated with BOF-4272 (a potent xanthine oxidase inhibitor) to investigate to what degree xanthine dehydrogenase participates in the oxidation of these agents. BOF-4272 markedly decreased the plasma concentration and the urinary excretion of both oxypurinol and 5-hydroxypyrazinamide. It also decreased the sum of the urinary excretion of allopurinol and oxypurinol and that of pyrazinamide and its metabolites, although it did not affect the sum of the plasma concentrations of allopurinol and oxypurinol at 105 min after administration of allopurinol or the plasma concentration of pyrazinamide during the period after the administration of pyrazinamide. These results suggested that BOF-4272 almost completely inhibited the oxidation of allopurinol and pyrazinamide and had some effect on the excretion and/or the tissue incorporation of these two compounds. Since the in vitro study demonstrated that BOF-4272 did not inhibit the activity of aldehyde oxidase, which oxidized both allopurinol to oxypurinol and pyrazinamide to 5-hydroxypyrazinamide, the results suggested that xanthine dehydrogenase was the more important enzyme in converting allopurinol to oxypurinol and pyrazinamide to 5-hydroxypyrazinamide.
Assuntos
Aldeído Oxirredutases/metabolismo , Alopurinol/metabolismo , Pirazinamida/metabolismo , Triazinas/farmacologia , Xantina Desidrogenase/metabolismo , Aldeído Oxidase , Alopurinol/urina , Animais , Hipoxantina Fosforribosiltransferase/metabolismo , Masculino , Oxirredução , Oxipurinol/sangue , Oxipurinol/urina , Pirazinamida/sangue , Pirazinamida/urina , Ratos , Ratos Wistar , Triazinas/sangue , Xantina Desidrogenase/antagonistas & inibidoresRESUMO
The uricostatic drug allopurinol (CAS 315-30-0) is used for treatment of hyperuricaemia and is mainly bio-transformed to the active metabolite oxipurinol (CAS 2465-59-0) in humans. A new assay was developed for the simultaneous determination of both compounds in plasma and urine using ultrafiltration and ion exchange purification steps for plasma and urine, respectively. Reversed-phase high-performance liquid chromatography with ultraviolet detection was applied for the separation and quantitation of both compounds. The limit of detection was 0.1 microgram/ml for both compounds in plasma and 0.2 and 0.5 microgram/ml for allopurinol and oxipurinol, respectively, in urine. Within-run and day-to-day precision of 3-5% and 5-7% was determined for plasma and 6-8% and 8-10% for urine analysis. The assays were further validated using liquid chromatography with photodiode array detection and by comparison with methods using protein precipitation as the purifying step. The high analytical recoveries, selectivity, sensitivity, accuracy and reproducibility were adequate for the measurement of both compounds in pharmacokinetic studies and for drug monitoring in patients on allopurinol therapy.
Assuntos
Alopurinol/análise , Oxipurinol/análise , Adulto , Alopurinol/sangue , Alopurinol/urina , Proteínas Sanguíneas/metabolismo , Cromatografia Líquida de Alta Pressão , Cromatografia por Troca Iônica , Humanos , Masculino , Oxipurinol/sangue , Oxipurinol/urina , Espectrofotometria Ultravioleta , UltrafiltraçãoRESUMO
Allopurinol is converted almost completely into a single active metabolite, oxipurinol, which has the same therapeutic pattern but a much longer elimination half-life than the parent compound. Therefore both allopurinol and oxipurinol were evaluated in our bioequivalence study in healthy volunteers comparing two allopurinol brands. Bioequivalence determination was based on the 90% confidence intervals (CI) of the area under the plasma concentration time curve from time zero to infinity (AUC0-infinity), of the area from time zero to the last measurable plasma concentration (AUC0-t (last)), and Cmax. Because of the lack of compound-specific criteria we used conventional limits for the bioequivalence range. Under these conditions the brand chosen as test preparation was judged to be bioequivalent to the reference form with respect to the extent of bioavailability, AUC0-infinity, and AUC0-t (last) of the parent drug. The CI of Cmax of allopurinol slightly exceeded the upper limit of 130%, so that bioequivalence was not confirmed with regard to the rate of bioavailability of the parent compound. The CI values of both AUC and Cmax of the active metabolite were tighter than those of allopurinol. In addition, the CI values of Cmax of oxipurinol were smaller than those of the corresponding AUC. As a consequence the test drug can clearly be accepted as bioequivalent, based on metabolite data. Since the active metabolite is of greater therapeutic significance than the parent drug, assessment of the bioequivalence of allopurinol preparations needs to be based on oxipurinol rather than allopurinol.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Alopurinol/farmacocinética , Oxipurinol/metabolismo , Adulto , Alopurinol/sangue , Alopurinol/urina , Disponibilidade Biológica , Humanos , Masculino , Reprodutibilidade dos Testes , Equivalência TerapêuticaRESUMO
A 74-year-old female was diagnosed as having xanthinuria by measurement of the uric acid level in plasma, purine bases in urine and activity of xanthine oxidase in the duodenal mucosa. The determination of the urinary excretion of purine bases in her family demonstrated a slightly increased urinary excretion of oxypurines in her younger brother, suggesting that he was a heterozygote. The pyrazinamide-loading test and allopurinol-loading test demonstrated that she could neither metabolize pyrazinoic acid into 5-hydroxypyrazinoic acid nor allopurinol into oxypurinol, although there was a slight metabolizing of prazinamide into 5-hydroxypyrazinamide. This suggested that she belonged to the subgroup which can neither metabolize pyrazinamide into 5-hydroxypyrazinamide, pyrazinoic acid into 5-hydroxypyrazinoic acid nor allopurinol into oxypurinol.
Assuntos
Xantinas/urina , Idoso , Alopurinol/urina , Creatinina/urina , Feminino , Humanos , Hipoxantina , Hipoxantinas/urina , Linhagem , Pirazinamida/metabolismo , Ácido Úrico/urina , Xantina , Xantina Oxidase/deficiênciaRESUMO
There are no safe and effective oral drugs to treat leishmaniasis and Chagas' disease. The safety, pharmacokinetics, and metabolism of single and multiple oral doses of allopurinol riboside, an investigational antiparasitic agent, were evaluated in a randomized, double-blinded, placebo-controlled study in 32 healthy male volunteers, at levels up to 25 mg/kg q.i.d. for 13 doses. No significant toxicity was detected. Allopurinol riboside peaks in plasma 1.6 hours after administration, has an elimination half-life of 3 hours, and steady-state concentrations in the therapeutic range. However, in contrast to preclinical studies in dogs (plasma levels proportional to oral doses up to 200 mg/kg), we found that plasma levels were unexpectedly low and did not rise with increasing dose. Furthermore, allopurinol and oxypurinol (unanticipated metabolites) were detected at levels proportional to the dose of allopurinol riboside. We present a model that includes incomplete absorption, metabolism of residual drug by enteric flora, and absorption of bacterial metabolites to explain these findings in humans.
Assuntos
Alopurinol/análogos & derivados , Antiprotozoários/farmacocinética , Ribonucleosídeos/farmacocinética , Adolescente , Adulto , Alopurinol/efeitos adversos , Alopurinol/sangue , Alopurinol/farmacocinética , Alopurinol/urina , Antiprotozoários/efeitos adversos , Antiprotozoários/sangue , Antiprotozoários/urina , Método Duplo-Cego , Avaliação de Medicamentos , Meia-Vida , Humanos , Análise dos Mínimos Quadrados , Masculino , Pessoa de Meia-Idade , Oxipurinol/sangue , Purinas/sangue , Ribonucleosídeos/efeitos adversos , Ribonucleosídeos/sangue , Ribonucleosídeos/urinaRESUMO
In order to study the effects and pharmacokinetics of allopurinol (hereafter abbreviated to allo.) and oxipurinol (hereafter abbreviated to oxi.) six normal human subjects were given a single oral dose of either allo. (300mg) or oxi. (600mg), followed by serial determinations of serum and urinary levels of allo., oxi., uric acid, hypoxanthine (hereafter abbreviated to hx.) and xanthine (hereafter abbreviated x.) over a six-hour period. With a dose of 300mg of allo. or 600mg of oxi., the patterns of serum uric acid were similar. When 300mg of allo. was given, however, a reduction in the serum uric acid level occurred earlier. Additionally, it was found that urinary excretion of oxi. generally paralleled the plasma concentration. Allo. administration resulted in rises in plasma concentration of x., and urinary excretion of x. and hx. Oxi. administration, on the other hand, did not cause significant changes in the plasma content of x. or urinary excretory volume of hx. Only a slight increase was noted in the amount of x. excreted in the urine. When allo. was compared against oxi., pharmacokinetics of oxypurines, especially x. were found to differ markedly. The results suggested that differences in the reaction sites, varied intra- and extra-cellular distributions of allo. and oxi., and different effects on purine biosynthesis contribute to the aforementioned discrepancies.
Assuntos
Alopurinol/farmacocinética , Oxipurinol/farmacocinética , Adulto , Alopurinol/sangue , Alopurinol/urina , Humanos , Hipoxantina , Hipoxantinas/sangue , Hipoxantinas/urina , Masculino , Oxipurinol/sangue , Oxipurinol/urina , Valores de Referência , Ácido Úrico/sangue , Ácido Úrico/urina , Xantina , Xantinas/sangue , Xantinas/urinaAssuntos
Alopurinol/farmacocinética , Benzobromarona/farmacocinética , Etanol/farmacologia , Adulto , Consumo de Bebidas Alcoólicas , Alopurinol/sangue , Alopurinol/urina , Benzobromarona/sangue , Benzobromarona/urina , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Tempo , Ácido Úrico/metabolismoRESUMO
The metabolism of pyrazinamide and allopurinol was studied in three xanthinuric patients from two families with hereditary xanthinuria to determine whether both substrates were oxidized only by xanthine oxidase or by other oxidases as well. One xanthinuric patient could neither metabolize pyrazinamide into 5-hydroxypyrazinamide nor allopurinol into oxypurinol. Two xanthinuric patients could metabolize both pyrazinamide into 5-hydroxypyrazinamide and allopurinol into oxypurinol but could not oxidize pyrazinoic acid to 5-hydroxypyrazinoic acid. These findings suggest that xanthinuria comprises at least two subgroups.